Single Biggest Cancer Dictionary in the World
What is KRAS-G12C inhibitor LY3537982?
Pronunciation: /kræs ʤi twɛlv si ˌɪnˈhɪbətər laɪ θri ˈmɪljən, faɪv ˈhənərd ənd thirty-seven* ˈθaʊzənd, naɪn ˈhənərd ənd eighty-two*/
KRAS-G12C inhibitor LY3537982
Definition
An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, KRAS-G12C inhibitor LY3537982 selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.